Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | RET | P07949 | 5/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199934 | 0.86 | KDM4E (0.71) | RAF1RETFLT3ROCK1EGFR | |
| SCHEMBL13200145 | 0.85 | RAF1 (0.53) | RAF1RIPK2RETFLT3MAPK13 | |
| SCHEMBL4444438 | 0.84 | RAF1 (0.72) | RAF1RIPK2FLT3MAPK13MAPK12 | |
| SCHEMBL102637 | 0.84 | RAF1 (0.72) | RAF1RIPK2FLT3MAPK13MAPK12 | |
| SCHEMBL13200780 | 0.82 | FLT3 (0.63) | RAF1RETFLT3ROCK1EGFR | |
| SCHEMBL13199933 | 0.82 | GAPDH (0.71) | RAF1RETFLT3ROCK1EGFR | |
| SCHEMBL668459 | 0.81 | RAF1 (1.00) | RAF1RIPK2FLT3MAPK13MAPK12 | |
| SCHEMBL9978507 | 0.81 | FLT3 (0.62) | RAF1RETFLT3ROCK1EGFR | |
| SCHEMBL1256800 | 0.81 | FLT3 (0.62) | RAF1RETFLT3MAPK14ROCK1 | |
| SCHEMBL13200476 | 0.80 | FLT3 (0.65) | RAF1RETFLT3MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | ABL1, ABL2, BCR | RAF1 372/4885RIPK2 3664/4885RET 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.